Ratings changes for Enphase Energy, Fermi, Maplight Therapeutics, Sanmina, Rivian Automotive, AXT, Amkor Technology and more...Upgrade to MarketBeat All Access to get our best stock ideas, proprietary research, portfolio monitoring tools, and more. Start Your Free Trial.

July 28th, 2026

Elon Musk’s “A.R.M” will change the world (Ad)

Elon Musk has already reshaped industries with PayPal, Tesla, and SpaceX. Now he is teasing something he calls his biggest product ever.
A live demo shows why this new project, dubbed A.R.M., is turning heads across the tech world.
One analyst has identified a way to follow this emerging opportunity closely.

Click here to see the full demo and details now

Today's Top Stories

Chips & Clips: Memory Tariffs Rewire Tech Supply Chains

By Jeffrey Neal Johnson | July 28, 2026 12:15 PM

Wall Street’s quietly buying these 3 AI infrastructure plays (Ad)

By StockEarnings

Is the Market Mispricing ServiceNow's AI Future?

By Sam Quirke | July 28, 2026 11:05 AM

Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus

By Jeffrey Neal Johnson | July 28, 2026 10:30 AM

The Great AI Meltdown is Coming (prepare now and get rich) (Ad)

By The Oxford Club

Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story

By Thomas Hughes | July 28, 2026 09:55 AM

5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys?

By Ryan Hasson | July 28, 2026 09:20 AM

Quick Links

Analyst Ratings My MarketBeat Account Settings MarketBeat All Access Stock Lists Stock Screener Calculators Premium Reports Best Stocks to Buy in July

Why did Trump “Redact” 750 White House Files?

Trump's $300 Million Check Raises One Very Strange Question (Ad)

President Trump reportedly redacted 750 White House files, then put 300 million dollars of his own money into a company tied to what may come next.
The files were meant to protect America from serious harm, yet they vanished from public view right before the investment surfaced.
Researchers have traced a possible connection between the redacted files and Trump's personal stake in this company.

Click here to see the hidden connection behind the story

Analysts' Upgrades

Gossamer Bio (NASDAQ:GOSS) was upgraded by Leerink Partners from "market perform" to "outperform". They now have a $1.00 price target on the stock. This represents a 415.5% upside from the current price of $0.19.

Honeywell International (NASDAQ:HON) was upgraded by Bank of America Corporation from "underperform" to "neutral". They now have a $265.00 price target on the stock, up from $205.00. This represents a 7.2% upside from the current price of $247.31.

International Paper (NYSE:IP) was upgraded by JPMorgan Chase & Co. from "neutral" to "overweight". They now have a $61.00 price target on the stock, up from $51.00. This represents a 38.8% upside from the current price of $43.93.

JBS (NYSE:JBS) was upgraded by JPMorgan Chase & Co. from "neutral" to "overweight". They now have a $18.00 price target on the stock. This represents a 29.7% upside from the current price of $13.88.

Lufax (NYSE:LU) was upgraded by JPMorgan Chase & Co. from "neutral" to "overweight". They now have a $2.00 price target on the stock. This represents a 27.0% upside from the current price of $1.58.

Magnolia Oil & Gas (NYSE:MGY) was upgraded by Truist Financial Corporation from "hold" to "buy". They now have a $33.00 price target on the stock, up from $32.00. This represents a 39.8% upside from the current price of $23.61.

Richardson Electronics (NASDAQ:RELL) was upgraded by Northland Securities from "market perform" to "outperform". They now have a $24.00 price target on the stock, up from $14.00. This represents a 26.5% upside from the current price of $18.98.

View More Upgrades

Forget SpaceX, stake a claim in Elon’s “A.R.M” instead (Ad)

James Altucher called Tesla's AI pivot in 2016, and the stock has since climbed as much as 31x. In 2024 he predicted SpaceX would go public in the biggest IPO in history, and it just did at a 1.77 trillion dollar valuation.
Now Altucher says he has uncovered Elon Musk's next project, something he calls A.R.M., which Musk has reportedly described as bigger than Tesla or SpaceX. The official rollout could come as soon as October 22nd.

Click here to see Altucher's full breakdown of Elon's next project

Analysts' Downgrades

Bank of Marin Bancorp (NASDAQ:BMRC) was downgraded by Brean Capital from "buy" to "neutral". They now have a $33.00 price target on the stock. This represents a 13.4% upside from the current price of $29.09.

Eastern Bankshares (NASDAQ:EBC) was downgraded by Stephens from "overweight" to "equal weight". They now have a $24.00 price target on the stock. This represents a 2.9% upside from the current price of $23.32.

ExxonMobil (NYSE:XOM) was downgraded by Bank of America Corporation from "buy" to "neutral". They now have a $158.00 price target on the stock, up from $154.00. This represents a 3.1% upside from the current price of $153.25.

PROCEPT BioRobotics (NASDAQ:PRCT) was downgraded by UBS Group AG from "buy" to "neutral". They now have a $20.00 price target on the stock. This represents a 10.2% upside from the current price of $18.15.

Spyre Therapeutics (NASDAQ:SYRE) was downgraded by Wolfe Research from "outperform" to "peer perform". The current price is $97.35.

View More Downgrades

Write This Down: A.R.M. (Ad)

A secretive project tied to Elon Musk, nicknamed ARM, has caught investors' attention. Musk has suggested it could be worth $25 trillion, more than the entire Mag Seven combined.
NVIDIA's CEO calls this space the next trillion dollar opportunity, and Cathie Wood's fund recently invested $1 billion in the company reportedly behind the project.

Watch the full video breakdown to learn more now

Analysts' New Coverage

Becton, Dickinson and Company (NYSE:BDX) is now covered by UBS Group AG. They set a "buy" rating on the stock. The current price is $165.44.

Beta Bionics (NASDAQ:BBNX) is now covered by UBS Group AG. They set a "buy" rating and a $22.00 price target on the stock. This represents a 39.1% upside from the current price of $15.82.

Edwards Lifesciences (NYSE:EW) is now covered by UBS Group AG. They set a "buy" rating and a $110.00 price target on the stock. This represents a 31.4% upside from the current price of $83.70.

Glaukos (NYSE:GKOS) is now covered by UBS Group AG. They set a "neutral" rating on the stock. The current price is $150.46.

GXO Logistics (NYSE:GXO) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $18.00 price target on the stock. This represents a 66.2% downside from the current price of $53.21.

H&R Block (NYSE:HRB) is now covered by Stephens. They set an "equal weight" rating and a $47.00 price target on the stock. This represents a 4.0% upside from the current price of $45.19.

Integra LifeSciences (NASDAQ:IART) is now covered by UBS Group AG. They set a "neutral" rating and a $19.00 price target on the stock. This represents a 5.3% downside from the current price of $20.06.

MiniMed Group (NASDAQ:MMED) is now covered by UBS Group AG. They set a "buy" rating and a $25.00 price target on the stock. This represents a 38.7% upside from the current price of $18.02.

Rapport Therapeutics (NASDAQ:RAPP) is now covered by William Blair. They set an "outperform" rating on the stock. The current price is $41.12.

Sensei Biotherapeutics (NASDAQ:FTH) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $60.00 price target on the stock. This represents a 105.7% upside from the current price of $29.17.

Shoulder Innovations (NYSE:SI) is now covered by UBS Group AG. They set a "buy" rating and a $27.00 price target on the stock. This represents a 17.5% upside from the current price of $22.98.

Sight Sciences (NASDAQ:SGHT) is now covered by UBS Group AG. They set a "buy" rating and a $7.00 price target on the stock. This represents a 31.7% upside from the current price of $5.32.

STAAR Surgical (NASDAQ:STAA) is now covered by UBS Group AG. They set a "sell" rating and a $20.00 price target on the stock. This represents a 11.8% downside from the current price of $22.67.

Tandem Diabetes Care (NASDAQ:TNDM) is now covered by UBS Group AG. They set a "neutral" rating and a $18.00 price target on the stock. This represents a 0.3% upside from the current price of $17.95.

Tenax Therapeutics (NASDAQ:TENX) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $35.00 price target on the stock. This represents a 123.3% upside from the current price of $15.68.

Cooper Companies (NASDAQ:COO) is now covered by UBS Group AG. They set a "neutral" rating and a $75.00 price target on the stock. This represents a 4.7% upside from the current price of $71.64.

TransMedics Group (NASDAQ:TMDX) is now covered by UBS Group AG. They set a "neutral" rating and a $80.00 price target on the stock. This represents a 6.5% upside from the current price of $75.14.

View More New Coverage

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial